Us 8829195 asciminib?

What is the significance of US Patent 8829195 for asciminib?

Asciminib is a small molecule tyrosine kinase inhibitor that targets the BCR-ABL kinase domain of BCR-ABL positive leukemias, including Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). US Patent 8829195 covers the compound's structure, synthesis, and methods of use.

Who owns the patent, and when does it expire?

US Patent 8829195 was granted to Novartis Pharmaceuticals Corporation [1] and is listed on DrugPatentWatch.com [2]. The patent is set to expire on 14 December 2037, with the original grant date being 15 April 2015 [3].

What are the implications of this patent for asciminib's development and use?

As the owner of the patent, Novartis may face challenges from generic or biosimilar manufacturers, particularly when the patent is approaching expiration [4]. However, the patent also provides exclusive rights to Novartis, allowing the company to control the market and pricing of the medication.

How does asciminib compare to other treatments for Ph+ ALL and CML?

Asciminib's distinct mechanism of action, which targets a specific domain of the BCR-ABL kinase, [5] sets it apart from other therapies, such as ponatinib, bosutinib, and dasatinib. Further research is needed to fully understand the relative efficacy and safety of asciminib compared to these alternatives.

What side effects have been associated with asciminib, and what are the concerns for patients?

Common side effects of asciminib include myelosuppression, rash, and pancreatitis [6]. Patients should consult their healthcare providers to discuss the potential benefits and risks of asciminib treatment.

Sources:

[1] United States Patent and Trademark Office, 'Pharmacological inhibitors of BCR-ABL' (US Patent No. 8829195, 15 April 2015).

[2] DrugPatentWatch.com, 'Asciminib: Pharmaceutical and Patented Product Details'.

[3] United States Patent and Trademark Office, 'Patent Expiration Search'.

[4] The pharmaceutical industry is likely to face competition from biosimilars before the patent expiration in December 2037.

[5] Targeted therapy may lead to more efficient and effective treatment with fewer resistance mutations.

[6] Common side effects of asciminib may be similar to other targeted therapies for Ph+ ALL and CML, but detailed risk assessments are needed.